Prevention & early treatment of the long-term physical effects of COVID-19 in adults: ..a randomised controlled trial of .. exercise, 2022, Morrow

Discussion in 'Long Covid research' started by Andy, Aug 16, 2022.

  1. Andy

    Andy Committee Member

    Messages:
    22,400
    Location:
    Hampshire, UK
    Full title: Prevention and early treatment of the long-term physical effects of COVID-19 in adults: design of a randomised controlled trial of resistance exercise—CISCO-21

    Abstract

    Background
    Coronavirus disease-19 (COVID-19) infection causes persistent health problems such as breathlessness, chest pain and fatigue, and therapies for the prevention and early treatment of post-COVID-19 syndromes are needed. Accordingly, we are investigating the effect of a resistance exercise intervention on exercise capacity and health status following COVID-19 infection.

    Methods
    A two-arm randomised, controlled clinical trial including 220 adults with a diagnosis of COVID-19 in the preceding 6 months. Participants will be classified according to clinical presentation: Group A, not hospitalised due to COVID but persisting symptoms for at least 4 weeks leading to medical review; Group B, discharged after an admission for COVID and with persistent symptoms for at least 4 weeks; or Group C, convalescing in hospital after an admission for COVID.

    Participants will be randomised to usual care or usual care plus a personalised and pragmatic resistance exercise intervention for 12 weeks. The primary outcome is the incremental shuttle walks test (ISWT) 3 months after randomisation with secondary outcomes including spirometry, grip strength, short performance physical battery (SPPB), frailty status, contacts with healthcare professionals, hospitalisation and questionnaires assessing health-related quality of life, physical activity, fatigue and dyspnoea.

    Discussion
    Ethical approval has been granted by the National Health Service (NHS) West of Scotland Research Ethics Committee (REC) (reference: GN20CA537) and recruitment is ongoing. Trial findings will be disseminated through patient and public forums, scientific conferences and journals.

    Open access, https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06632-y
     
    Peter Trewhitt, RedFox and Trish like this.
  2. Andy

    Andy Committee Member

    Messages:
    22,400
    Location:
    Hampshire, UK

Share This Page